𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Parkinson’s disease: oxidative stress and therapeutic approaches

✍ Scribed by Sankar Surendran; Srinivasagam Rajasankar

Publisher
Springer Milan
Year
2010
Tongue
English
Weight
273 KB
Volume
31
Category
Article
ISSN
1590-1874

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Oxidative stress in Parkinson's disease
Oxidative stress in Parkinson's disease
✍ Peter Jenner 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 121 KB 👁 3 views

Oxidative stress contributes to the cascade leading to dopamine cell degeneration in Parkinson's disease (PD). However, oxidative stress is intimately linked to other components of the degenerative process, such as mitochondrial dysfunction, excitotoxicity, nitric oxide toxicity and inflammation. It

Therapeutic directions for Parkinson's d
Therapeutic directions for Parkinson's disease
✍ Ira Shoulson 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 51 KB

## Abstract The focus on disease‐modifying treatments and cures for Parkinson's disease (PD) has raised expectations for quantum leaps and overshadowed incremental gains that have been slowly achieved. Large multi‐center clinical trials such as DATATOP and PRECEPT keep on generating new knowledge t

Neutrophil function, nitric oxide, and b
Neutrophil function, nitric oxide, and blood oxidative stress in Parkinson's disease
✍ Dr. Emilia M. Gatto; María C. Carreras; Griselda A. Pargament; Natalia A. Riobo; 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 614 KB

## Abstract We studied nitrogen radical nitric oxide (.NO) release and reactive oxygen species (ROS) production by isolated neurophils after phorbol myristate acetate (PMA) stimulation in 12 newly diagnosed and nine treated Parkinson's disease (PD) patients and 10 age‐matched healthy controls. Neut

Milestones in Parkinson's disease therap
Milestones in Parkinson's disease therapeutics
✍ Olivier Rascol; Andres Lozano; Matthew Stern; Werner Poewe 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 228 KB

## Abstract In the mid‐1980s, the treatment of Parkinson's disease was quite exclusively centered on dopatherapy and was focusing on dopamine systems and motor symptoms. A few dopamine agonists and a monoamine oxidase B inhibitor (selegiline) were used as adjuncts in advanced Parkinson's disease. I